HOXD13 and acute lymphoblastic leukemia: In addition, it has been demonstrated that release of sPD-1 strengthen CAR-T cytotoxicity against CD19+ pediatric acute lymphoblastic leukemia cell line and breast cancer cells further demonstrating how sPD-1 could represent a successful therapeutic strategy (30, 31).